[HTML][HTML] Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression

BJ Langford, M So, V Leung, S Raybardhan… - Clinical Microbiology …, 2022 - Elsevier
Background The prevalence of bacterial infection in patients with COVID-19 is low, however,
empiric antibiotic use is high. Risk stratification may be needed to minimize unnecessary …

Racial and ethnic discrepancy in pulse oximetry and delayed identification of treatment eligibility among patients with COVID-19

A Fawzy, TD Wu, K Wang, ML Robinson… - JAMA internal …, 2022 - jamanetwork.com
Importance Pulse oximetry guides triage and therapy decisions for COVID-19. Whether
reported racial inaccuracies in oxygen saturation measured by pulse oximetry are present in …

Inflammatory pathways in COVID‐19: mechanism and therapeutic interventions

Y Jiang, T Zhao, X Zhou, Y **ang… - MedComm, 2022 - Wiley Online Library
Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …

Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19

BT Garibaldi, K Wang, ML Robinson… - JAMA network …, 2021 - jamanetwork.com
Importance Clinical effectiveness data on remdesivir are urgently needed, especially among
diverse populations and in combination with other therapies. Objective To examine whether …

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial

MS Niaee, P Namdar, A Allami, L Zolghadr… - Asian Pacific Journal …, 2021 - journals.lww.com
Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and
to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A …

Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study

BT Garibaldi, K Wang, ML Robinson… - Clinical Infectious …, 2022 - academic.oup.com
Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Development of severe COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19

S Wongvibulsin, BT Garibaldi, AAR Antar… - Annals of internal …, 2021 - acpjournals.org
Background: Predicting the clinical trajectory of individual patients hospitalized with
coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care …

Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to …

C Campbell, MI Andersson, MA Ansari… - Frontiers in …, 2021 - frontiersin.org
Objectives: Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of severe
COVID-19 caused by infection with SARS-CoV-2. However, unintended consequences of …

Clinical features and outcomes of coronavirus disease 2019 among people with human immunodeficiency virus in the United States: a multicenter study from a large …

GA Yendewa, JA Perez, K Schlick… - Open forum …, 2021 - academic.oup.com
Background Human immunodeficiency virus infection (HIV) is a presumed risk factor for
severe coronavirus disease 2019 (COVID-19), yet little is known about COVID-19 outcomes …

The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials

WT Lin, SH Hung, CC Lai, CY Wang… - International …, 2021 - Elsevier
Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of tocilizumab for treating patients with …